NCT05370950View on ClinicalTrials.gov

Study of Bioavailability, Pharmacodynamics and Safety of SHR-1209 Administered by Single Subcutaneous Injection at Different Sites in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

May 25, 2022

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Hypercholesterolemia and Hyperlipidemia
Interventions
DRUG

SHR-1209

SHR-1209，single subcutaneous injection of 450mg

Trial Locations (1)

230601

The Second Affiliated Hospital of Anhui Medical University, Hefei

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY